Andrew Nelson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Andrew Nelson has a total of 323 co-authors. Here are the top co-authors by number of shared publications:
- Christopher James Stewart
Translational and Clinical Research Institute Newcastle University Newcastle upon Tyne UK
20 shared publications - Stephen Peter Cummings
Victoria University of Wellington
17 shared publications - Nicholas David Embleton
Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK
11 shared publications John D. Perry
Freeman Hospital, Newcastle upon Tyne, United Kingdom
9 shared publications- Darren Lee Smith
Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne NE1 8ST, UK; Hub for Biotechnology in the Built Environment, Northumbria University, Newcastle upon Tyne NE1 8ST, UK
8 shared publications - John D. Perry
Microbiology Department, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
8 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Microbiome and immune development in preterm infants receiving powdered human milk‐based fortification from the PUFFIN trial
Objective: To determine the impact of powdered human milk‐based fortification (PHMF) compared to powdered bovine milk‐based fortification on gut microbiome and inflammation in preterm infants. Methods: Mechanistic study within randomised controlled trial in infants p = 0.04; 25.7% at D21, p = 0.007). Stool but not urine sIgA was higher in PHMF recipients. Whilst fortifier type was not associated with IRPs from D7 to D21, NICU site impacted IRPs. Conclusions: Fortifier type did not have a large impact on microbiota or IRPs but stool sIgA was higher in PHMF recipients. An association between NICU site and other outcomes was observed. Trial Registration: ClinicalTrials.gov identifier: The Preterm milk fortification in neonates (PUFFIN) study was prospectively registered ISRCTN 22484792.
- 10 November 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Open AccessMicrobiome and immune development in preterm infants receiving powdered human milk‐based fortification from the PUFFIN trial
Objective: To determine the impact of powdered human milk‐based fortification (PHMF) compared to powdered bovine milk‐based fortification on gut microbiome and inflammation in preterm infants. Methods: Mechanistic study within randomised controlled trial in infants p = 0.04; 25.7% at D21, p = 0.007). Stool but not urine sIgA was higher in PHMF recipients. Whilst fortifier type was not associated with IRPs from D7 to D21, NICU site impacted IRPs. Conclusions: Fortifier type did not have a large impact on microbiota or IRPs but stool sIgA was higher in PHMF recipients. An association between NICU site and other outcomes was observed. Trial Registration: ClinicalTrials.gov identifier: The Preterm milk fortification in neonates (PUFFIN) study was prospectively registered ISRCTN 22484792.
- Open Access
- 23 July 2026
- Published by Springer Nature in European Journal of Nutrition
- Vol. 65 (5) , 220
Distinct effects of supplementation with resistant starch and polydextrose on plasma and faecal bile acid profile and associations with gut microbiota: a randomised, controlled intervention in healthy participants
Purpose: Dietary fibre may influence bile acid (BA) metabolism via interactions with gut microbiota. We hypothesised that dietary fibres with distinct fermentative properties, resistant starch (RS) and polydextrose (PD), would differentially alter BA profiles in plasma and faeces through gut microbiota-mediated mechanisms. Methods: BA profiles were analysed by ultra-performance liquid chromatography mass spectrometry in plasma ( n = 74) and faeces ( n = 50) from a double-blind, randomised, placebo-controlled 2 × 2 factorial trial. Healthy participants consumed 23 g/day Hi-maize ® 260 (type 2 RS) and/or 12 g/day Litesse ® Ultra™ (PD) for 50 days. The intervention effects of RS and PD on BA profile were investigated using general linear models and beta regression models. Genus abundances derived from 16 S rRNA gene sequencing were used to investigate fibre-specific microbial correlations with BA profiles. Results: Supplementation with RS, but not PD, increased a range of conjugated BAs and deoxycholic acid (FDR < 0.05). Concentrations of taurochenodeoxycholic acid (FDR = 0.027) and taurine conjugated BAs (FDR = 0.049) in plasma correlated positively with Akkermansia abundance in response to RS. Although neither RS nor PD altered BA concentrations in faeces, RS decreased ( p = 0.032) and PD increased ( p = 0.012) faecal proportions of primary BAs. PD reduced secondary BA transformation ratios ( p < 0.05), along with shifts in related microbial associations. There were negative correlations between plasma primary conjugated BAs and faecal secondary BAs in response to RS specifically ( p < 0.05). Conclusion: RS increased plasma BAs, particularly conjugated BAs, whereas PD reduced faecal secondary BA transformation. The distinct impacts of RS and PD on BA profiles and fibre-specific microbial associations may underlie their differential metabolic effects. Trail registration The DISC Study was registered with https://clinicaltrials.gov/ (Identifier NCT01214681) in 2010.
- 23 July 2026
- Published by Springer Nature in European Journal of Nutrition
- Vol. 65 (5) , 220
Open AccessDistinct effects of supplementation with resistant starch and polydextrose on plasma and faecal bile acid profile and associations with gut microbiota: a randomised, controlled intervention in healthy participants
Purpose: Dietary fibre may influence bile acid (BA) metabolism via interactions with gut microbiota. We hypothesised that dietary fibres with distinct fermentative properties, resistant starch (RS) and polydextrose (PD), would differentially alter BA profiles in plasma and faeces through gut microbiota-mediated mechanisms. Methods: BA profiles were analysed by ultra-performance liquid chromatography mass spectrometry in plasma ( n = 74) and faeces ( n = 50) from a double-blind, randomised, placebo-controlled 2 × 2 factorial trial. Healthy participants consumed 23 g/day Hi-maize ® 260 (type 2 RS) and/or 12 g/day Litesse ® Ultra™ (PD) for 50 days. The intervention effects of RS and PD on BA profile were investigated using general linear models and beta regression models. Genus abundances derived from 16 S rRNA gene sequencing were used to investigate fibre-specific microbial correlations with BA profiles. Results: Supplementation with RS, but not PD, increased a range of conjugated BAs and deoxycholic acid (FDR < 0.05). Concentrations of taurochenodeoxycholic acid (FDR = 0.027) and taurine conjugated BAs (FDR = 0.049) in plasma correlated positively with Akkermansia abundance in response to RS. Although neither RS nor PD altered BA concentrations in faeces, RS decreased ( p = 0.032) and PD increased ( p = 0.012) faecal proportions of primary BAs. PD reduced secondary BA transformation ratios ( p < 0.05), along with shifts in related microbial associations. There were negative correlations between plasma primary conjugated BAs and faecal secondary BAs in response to RS specifically ( p < 0.05). Conclusion: RS increased plasma BAs, particularly conjugated BAs, whereas PD reduced faecal secondary BA transformation. The distinct impacts of RS and PD on BA profiles and fibre-specific microbial associations may underlie their differential metabolic effects. Trail registration The DISC Study was registered with https://clinicaltrials.gov/ (Identifier NCT01214681) in 2010.
- Open Access
- 30 April 2026
- Published by Elsevier in Forensic Science International: Genetics
- Vol. 84, 103517
Microbial decomposition in experimental single and mass graves: New insights on post-burial interval estimation
- 30 April 2026
- Published by Elsevier in Forensic Science International: Genetics
- Vol. 84, 103517
Open AccessMicrobial decomposition in experimental single and mass graves: New insights on post-burial interval estimation
- Open Access
- 25 November 2025
- Published by Elsevier in Forensic Science International: Genetics
- Vol. 82, 103395
Oral microbiomes as forensic markers of origin and migration: Insights from an underrepresented population, Nigeria
- 25 November 2025
- Published by Elsevier in Forensic Science International: Genetics
- Vol. 82, 103395
Open AccessOral microbiomes as forensic markers of origin and migration: Insights from an underrepresented population, Nigeria
- Open Access
Human milk oligosaccharide metabolism by Clostridium species suppresses inflammation and pathogen growth
Gut microbiome development is strongly impacted by breastmilk and human milk oligosaccharides (HMOs), with short- and long-term health implications. HMO metabolism is best characterised within bifidobacteria, but the full range of other HMO-utilising species remains unknown. This study examined HMO-utilising bacteria that colonise preterm infants (born Clostridium perfringens , and three other Clostridium species, metabolise HMOs, producing short chain fatty acids, tryptophan catabolites, and other metabolites known to improve host health. C. perfringens inhibited pathobiont growth and supressed inflammation in preterm-derived intestinal organoids. These findings suggest a previously unrecognised role for C. perfringens , specifically those lacking the perfringolysin O gene, in promoting healthy gut development during infancy.
Open AccessHuman milk oligosaccharide metabolism by Clostridium species suppresses inflammation and pathogen growth
Gut microbiome development is strongly impacted by breastmilk and human milk oligosaccharides (HMOs), with short- and long-term health implications. HMO metabolism is best characterised within bifidobacteria, but the full range of other HMO-utilising species remains unknown. This study examined HMO-utilising bacteria that colonise preterm infants (born Clostridium perfringens , and three other Clostridium species, metabolise HMOs, producing short chain fatty acids, tryptophan catabolites, and other metabolites known to improve host health. C. perfringens inhibited pathobiont growth and supressed inflammation in preterm-derived intestinal organoids. These findings suggest a previously unrecognised role for C. perfringens , specifically those lacking the perfringolysin O gene, in promoting healthy gut development during infancy.
- Open Access
Addressing pandemic-wide systematic errors in the SARS-CoV-2 phylogeny
The SARS-CoV-2 genome occupies a unique place in infection biology – it is the most highly sequenced genome on earth (making up over 20% of public sequencing datasets) with fine scale information on sampling date and geography, and has been subject to unprecedented intense analysis. As a result, these phylogenetic data are an incredibly valuable resource for science and public health. However, the vast majority of the data was sequenced by tiling amplicons across the full genome, with amplicon schemes that changed over the pandemic as mutations in the viral genome interacted with primer binding sites. In combination with the disparate set of genome assembly workflows and lack of consistent quality control (QC) processes, the current genomes have many systematic errors that have evolved with the virus and amplicon schemes. These errors have significant impacts on the phylogeny, and therefore over the last few years, many thousands of hours of researchers time has been spent in “eyeballing” trees, looking for artefacts, and then patching the tree. Given the huge value of this dataset, we therefore set out to reprocess the complete set of public raw sequence data in a rigorous amplicon-aware manner, and build a cleaner phylogeny. Here we provide a global tree of 4,471,579 samples, built from a consistently assembled set of high quality consensus sequences from all available public data as of June 2024, viewable at https://viridian.taxonium.org . Each genome was constructed using a novel assembly tool called Viridian ( https://github.com/iqbal-lab-org/viridian ), developed specifically to process amplicon sequence data, eliminating artefactual errors and mask the genome at low quality positions. We provide simulation and empirical validation of the methodology, and quantify the improvement in the phylogeny. We hope the tree, consensus sequences and Viridian will be a valuable resource for researchers.
Open AccessAddressing pandemic-wide systematic errors in the SARS-CoV-2 phylogeny
The SARS-CoV-2 genome occupies a unique place in infection biology – it is the most highly sequenced genome on earth (making up over 20% of public sequencing datasets) with fine scale information on sampling date and geography, and has been subject to unprecedented intense analysis. As a result, these phylogenetic data are an incredibly valuable resource for science and public health. However, the vast majority of the data was sequenced by tiling amplicons across the full genome, with amplicon schemes that changed over the pandemic as mutations in the viral genome interacted with primer binding sites. In combination with the disparate set of genome assembly workflows and lack of consistent quality control (QC) processes, the current genomes have many systematic errors that have evolved with the virus and amplicon schemes. These errors have significant impacts on the phylogeny, and therefore over the last few years, many thousands of hours of researchers time has been spent in “eyeballing” trees, looking for artefacts, and then patching the tree. Given the huge value of this dataset, we therefore set out to reprocess the complete set of public raw sequence data in a rigorous amplicon-aware manner, and build a cleaner phylogeny. Here we provide a global tree of 4,471,579 samples, built from a consistently assembled set of high quality consensus sequences from all available public data as of June 2024, viewable at https://viridian.taxonium.org . Each genome was constructed using a novel assembly tool called Viridian ( https://github.com/iqbal-lab-org/viridian ), developed specifically to process amplicon sequence data, eliminating artefactual errors and mask the genome at low quality positions. We provide simulation and empirical validation of the methodology, and quantify the improvement in the phylogeny. We hope the tree, consensus sequences and Viridian will be a valuable resource for researchers.
- Open Access
- 27 July 2021
- Published by MDPI AG in Microorganisms
- Vol. 9 (8) , 1597
Decontamination Strategies Used for AFB Culture Significantly Reduce the Viability of Mycobacterium abscessus Complex in Sputum Samples from Patients with Cystic Fibrosis
Nontuberculous mycobacteria are important respiratory pathogens in patients with cystic fibrosis (CF). For diagnosis, international guidelines recommend culture of sputum that has been decontaminated via chemical treatment. Fifty-six sputum samples from 32 patients known to be previously colonized or infected with NTM were subdivided, and the aliquots were subjected to six different decontamination strategies, followed by quantitative culture for NTM. Thirty sputum samples contained Mycobacterium abscessus complex (MABSC) and 11 contained Mycobacterium avium complex (MAC). Decontamination strategies included treatment with N-acetyl L-cysteine with 2% sodium hydroxide (NALC-NaOH), 4% NaOH, 1% chlorhexidine, 0.5 N sulfuric acid, 5% oxalic acid, double decontamination with NALC-NaOH, followed by 5% oxalic acid, and saline (0.85%) as a control. The samples were also cultured directly with no treatment. Treatment with NALC-NaOH resulted in an average reduction in colony count of 87% for MABSC when compared with direct culture. NaOH at 4% caused a 98.3% average reduction in colony count. All treatments that included NaOH resulted in colony counts that were statistically lower than those obtained from direct culture or the saline-treated control (p < 0.05). Standard treatments using sulfuric or oxalic acids were less deleterious, but still resulted in an average reduction in colony count of at least 30%. The viability of MAC was much less affected by most decontamination treatments. In conclusion, the viability of MABSC was severely compromised by standard decontamination regimens. This supports recent evidence showing that optimal recovery of MABSC is achieved by culture on an appropriate selective agar without decontamination of sputum samples.
- 27 July 2021
- Published by MDPI AG in Microorganisms
- Vol. 9 (8) , 1597
Open AccessDecontamination Strategies Used for AFB Culture Significantly Reduce the Viability of Mycobacterium abscessus Complex in Sputum Samples from Patients with Cystic Fibrosis
Nontuberculous mycobacteria are important respiratory pathogens in patients with cystic fibrosis (CF). For diagnosis, international guidelines recommend culture of sputum that has been decontaminated via chemical treatment. Fifty-six sputum samples from 32 patients known to be previously colonized or infected with NTM were subdivided, and the aliquots were subjected to six different decontamination strategies, followed by quantitative culture for NTM. Thirty sputum samples contained Mycobacterium abscessus complex (MABSC) and 11 contained Mycobacterium avium complex (MAC). Decontamination strategies included treatment with N-acetyl L-cysteine with 2% sodium hydroxide (NALC-NaOH), 4% NaOH, 1% chlorhexidine, 0.5 N sulfuric acid, 5% oxalic acid, double decontamination with NALC-NaOH, followed by 5% oxalic acid, and saline (0.85%) as a control. The samples were also cultured directly with no treatment. Treatment with NALC-NaOH resulted in an average reduction in colony count of 87% for MABSC when compared with direct culture. NaOH at 4% caused a 98.3% average reduction in colony count. All treatments that included NaOH resulted in colony counts that were statistically lower than those obtained from direct culture or the saline-treated control (p < 0.05). Standard treatments using sulfuric or oxalic acids were less deleterious, but still resulted in an average reduction in colony count of at least 30%. The viability of MAC was much less affected by most decontamination treatments. In conclusion, the viability of MABSC was severely compromised by standard decontamination regimens. This supports recent evidence showing that optimal recovery of MABSC is achieved by culture on an appropriate selective agar without decontamination of sputum samples.
- Open Access
- 29 October 2020
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 15 (5) , 800-812
The Impact ofNOD2Genetic Variants on the Gut Mycobiota in Crohn’s Disease Patients in Remission and in Individuals Without Gastrointestinal Inflammation
Historical and emerging data implicate fungi in Crohn’s disease [CD] pathogenesis. However, a causal link between mycobiota, dysregulated immunity, and any impact of NOD2 variants remains elusive. This study aims to evaluate associations between NOD2 variants and faecal mycobiota in CD patients and non-CD subjects. Faecal samples were obtained from 34 CD patients [18 NOD2 mutant, 16 NOD2 wild-type] identified from the UK IBD Genetics Consortium. To avoid confounding influence of mucosal inflammation, CD patients were in clinical remission and had a faecal calprotectin NOD2 mutant] and 25 non-household subjects with known NOD2 genotype [14 NOD2 mutant] identified by the NIHR BioResource Cambridge. Faecal mycobiota composition was determined using internal transcribed spacer 1 [ITS1] sequencing and was compared with 16S rRNA gene sequences and volatile organic compounds. CD was associated with higher numbers of fungal observed taxonomic units [OTUs] [p = 0.033]. Principal coordinates analysis using Jaccard index [p = 0.018] and weighted Bray‐Curtis dissimilarities [p = 0.01] showed Candida spp. clustered closer to CD patients whereas Cryptococcus spp. clustered closer to non-CD. In CD, we found higher relative abundance of Ascomycota [p = 0.001] and lower relative abundance Basidiomycota [p = 0.019] phyla. An inverse relationship was found between bacterial and fungal Shannon diversity in NOD2 wild-type which was independent of CD [r = -0.349; p = 0.029]. This study confirms compositional changes in the gut mycobiota in CD and provides evidence that fungi may play a role in CD pathogenesis. No NOD2 genotype-specific differences were observed in the faecal mycobiota.
- 29 October 2020
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 15 (5) , 800-812
Open AccessThe Impact ofNOD2Genetic Variants on the Gut Mycobiota in Crohn’s Disease Patients in Remission and in Individuals Without Gastrointestinal Inflammation
Historical and emerging data implicate fungi in Crohn’s disease [CD] pathogenesis. However, a causal link between mycobiota, dysregulated immunity, and any impact of NOD2 variants remains elusive. This study aims to evaluate associations between NOD2 variants and faecal mycobiota in CD patients and non-CD subjects. Faecal samples were obtained from 34 CD patients [18 NOD2 mutant, 16 NOD2 wild-type] identified from the UK IBD Genetics Consortium. To avoid confounding influence of mucosal inflammation, CD patients were in clinical remission and had a faecal calprotectin NOD2 mutant] and 25 non-household subjects with known NOD2 genotype [14 NOD2 mutant] identified by the NIHR BioResource Cambridge. Faecal mycobiota composition was determined using internal transcribed spacer 1 [ITS1] sequencing and was compared with 16S rRNA gene sequences and volatile organic compounds. CD was associated with higher numbers of fungal observed taxonomic units [OTUs] [p = 0.033]. Principal coordinates analysis using Jaccard index [p = 0.018] and weighted Bray‐Curtis dissimilarities [p = 0.01] showed Candida spp. clustered closer to CD patients whereas Cryptococcus spp. clustered closer to non-CD. In CD, we found higher relative abundance of Ascomycota [p = 0.001] and lower relative abundance Basidiomycota [p = 0.019] phyla. An inverse relationship was found between bacterial and fungal Shannon diversity in NOD2 wild-type which was independent of CD [r = -0.349; p = 0.029]. This study confirms compositional changes in the gut mycobiota in CD and provides evidence that fungi may play a role in CD pathogenesis. No NOD2 genotype-specific differences were observed in the faecal mycobiota.
- Open Access
YerA41, a Yersinia ruckeri Bacteriophage: Determination of a Non-Sequencable DNA Bacteriophage Genome via RNA-Sequencing
YerA41 is a Myoviridae bacteriophage that was originally isolated due its ability to infect Yersinia ruckeri bacteria, the causative agent of enteric redmouth disease of salmonid fish. Several attempts to determine its genomic DNA sequence using traditional and next generation sequencing technologies failed, indicating that the phage genome is modified in such a way that it is an unsuitable template for PCR amplification and for conventional sequencing. To determine the YerA41 genome sequence, we performed RNA-sequencing from phage-infected Y. ruckeri cells at different time points post-infection. The host-genome specific reads were subtracted and de novo assembly was performed on the remaining unaligned reads. This resulted in nine phage-specific scaffolds with a total length of 143 kb that shared only low level and scattered identity to known sequences deposited in DNA databases. Annotation of the sequences revealed 201 predicted genes, most of which found no homologs in the databases. Proteome studies identified altogether 63 phage particle-associated proteins. The RNA-sequencing data were used to characterize the transcriptional control of YerA41 and to investigate its impact on the bacterial gene expression. Overall, our results indicate that RNA-sequencing can be successfully used to obtain the genomic sequence of non-sequencable phages, providing simultaneous information about the phage–host interactions during the process of infection.
Open AccessYerA41, a Yersinia ruckeri Bacteriophage: Determination of a Non-Sequencable DNA Bacteriophage Genome via RNA-Sequencing
YerA41 is a Myoviridae bacteriophage that was originally isolated due its ability to infect Yersinia ruckeri bacteria, the causative agent of enteric redmouth disease of salmonid fish. Several attempts to determine its genomic DNA sequence using traditional and next generation sequencing technologies failed, indicating that the phage genome is modified in such a way that it is an unsuitable template for PCR amplification and for conventional sequencing. To determine the YerA41 genome sequence, we performed RNA-sequencing from phage-infected Y. ruckeri cells at different time points post-infection. The host-genome specific reads were subtracted and de novo assembly was performed on the remaining unaligned reads. This resulted in nine phage-specific scaffolds with a total length of 143 kb that shared only low level and scattered identity to known sequences deposited in DNA databases. Annotation of the sequences revealed 201 predicted genes, most of which found no homologs in the databases. Proteome studies identified altogether 63 phage particle-associated proteins. The RNA-sequencing data were used to characterize the transcriptional control of YerA41 and to investigate its impact on the bacterial gene expression. Overall, our results indicate that RNA-sequencing can be successfully used to obtain the genomic sequence of non-sequencable phages, providing simultaneous information about the phage–host interactions during the process of infection.
- 9 March 2020
- Published by Springer Nature
- Vol. 2121, 165-184
Microbiota Analysis Using Sequencing by Synthesis: From Library Preparation to Sequencing
The highly parallel nature of sequencing by synthesis (SBS) allows millions of amplicons to be sequenced simultaneously, which has led to enormous interest in the investigation of bacterial communities (often referred to as the microbiota). In this protocol, we describe a method for the ‘universal’ amplification of the v4 region of the bacterial 16S rRNA gene from genomic DNA and prepare these amplicons so that they can be sequenced using the MiSeq system (Illumina). The protocol provides instruction on sequencing of 188 genomic DNA samples plus PCR positive and negative controls, which can be applied to any sample type where bacterial DNA may be of interest.
- 9 March 2020
- Published by Springer Nature
- Vol. 2121, 165-184
Microbiota Analysis Using Sequencing by Synthesis: From Library Preparation to Sequencing
The highly parallel nature of sequencing by synthesis (SBS) allows millions of amplicons to be sequenced simultaneously, which has led to enormous interest in the investigation of bacterial communities (often referred to as the microbiota). In this protocol, we describe a method for the ‘universal’ amplification of the v4 region of the bacterial 16S rRNA gene from genomic DNA and prepare these amplicons so that they can be sequenced using the MiSeq system (Illumina). The protocol provides instruction on sequencing of 188 genomic DNA samples plus PCR positive and negative controls, which can be applied to any sample type where bacterial DNA may be of interest.